Roche Drug Pipeline

Roche maintains a substantial clinical portfolio, with 224 active trials and a total of 1606 trials registered since 2008. The active pipeline spans all phases of clinical development, with 71 programs in Phase 1, 82 in Phase 2, 93 in Phase 3, and 10 in Phase 4. These programs cover 12 distinct therapeutic areas, although activity is heavily concentrated in oncology, which accounts for 62% of active programs (138 trials). Within oncology, the leading indications by active trial count are breast cancer (24 active, 11 in Phase 3), advanced solid tumors (21 active, 6 in Phase 3), non-small cell lung cancer (19 active, 10 in Phase 3), and non-Hodgkin lymphoma (18 active, 6 in Phase 3). Outside of oncology, central nervous system disorders (31 active trials) and immunology (17 active trials) represent the next largest areas of clinical investigation, followed by metabolic diseases (15 active), rare diseases (10 active), and ophthalmology (10 active). The relatively high number of Phase 3 trials, particularly within oncology, suggests a potential for near-term data readouts and regulatory submissions.